Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00408603
Status:
COMPLETED
Last Update Posted:
2017-07-27
First Post:
2006-12-05
Brief Title:
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Sponsor:
Sunesis Pharmaceuticals
Organization:
Sunesis Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Open-Label Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the objective response rate safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle
Detailed Description:
Other objectives of this study are to evaluate Progression-free survival and measure CA-125 response rate
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None